Highlights beim Bronchialkarzinom

 

Covid-19 und Lungenkrebs

  • TERAVOLT-Studie: internationale Studie zum Verlauf von COVID-19-erkrankten Lungenkrebspatienten

Early Stage

  • ADAURA-Studie: Osimertinib im adjuvanten Setting beim EGFR-mutierten NSCLC
  • CTONG1104-Studie: Gefitinib adjuvant vs. Chemotherapie beim EGFR-mutierten NSCLC

Zielgerichtete Therapie

  • SINDAS-Studie: Radiotherapie beim oligmetastasierten EGFR-mutierten NSCLC
  • GEOMETRY-mono 1-Studie: Capmatinib beim met-amplifizierten NSCLC (Gene-Copy-Number >10)
  • DESTINY-Lung01-Studie: Trastuzumab deruxtecan beim HER2-mutierten NSCLC
  • ALEX-Studie: OS-Update zu Alectinib vs. Crizotinib als Erstlinientherapie des ALK+ NSCLC
  • ALTA-1L-Studie: Liquid-biopsy-Daten zu Brigatinib vs. Crizotinib als Erstlinientherapie des ALK+ NSCLC

Small Cell Lung Cancer (SCLC)

  • CASPIAN-Studie: Update zur Durvalumab ± Tremelimumab + Platin-Etoposid als Erstlinientherapie des SCLC extensive-stage (ES-SCLC)
  • KEYNOTE-604: Etoposid plus Platin +/- Pembrolizumab als Erstlinientherapie des SCLC extensive-stage (ES-SCLC)
  • ECOG-ACRIN-EA5161-Studie: Cisplatin/Carboplatin plus Etoposid alleine oder in Kombination mit Nivolumab als Erstlinientherapie des SCLC extensive Stage (ES-SCLC)
  • LD-SCLC: Randomisierte Phase-II-Studie zur Standardradiotherapie vs. Hochdosisradiotherapie (zweimal täglich 60Gy) bei limited disease SCLC (LD-SCLC).

Nichtkleinzelliges Bronchialkarzinom, NSCLC Stadium IV

  • CITYSCAPE-Studie: Anti-TIGIT-Antikörper Tiragolumab plus Atezolizumab beim metastasierten NSCLC (die Substanz wird in Österreich in der SKYSCRAPER-Studie angeboten)
  • CheckMate-9LA-Studie: Nivolumab + Ipilimumab + 2 Zyklen Platin-Doublet-Chemotherapy vs 4 Zyklen Chemotherapie als NSCLC-Erstlinientherapie
  • KEYNOTE-189-Studie: Finale Analyse zu Pemetrexed-Platin +/- Pembrolizumab als Erstlinientherapie des NSCLC.
  • CheckMate 227 Part 1: 3-Jahres-Update Nivolumab+Ipilimumab vs. Doublet-Chemotherapie

Malignes Pleuramesotheliom

  • PrE0505-Studie: Durvalumab in Kombination mit Cisplatin und Pemetrexed als Erstlinientherapie des nichtresezierbaren malignen Pleuramesothelioms (PrECOG LLC Studie).
  • RAMES-Studie: Phase-II-Studie mit Gemcitabin +/- Ramucirumab als Zweitlinientherapie des fortgeschrittenen malignen Pleuramesothelioms

 

 

Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. Leora Horn et al., ASCO20 virtual, LBA111

Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Roy S. Herbst et al., ASCO20 virtual, LBA5

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. Yi-Long Wu et al., ASCO20 virtual, Abstr. #9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332). Xiaoshan Wang et al., ASCO20 virtual, Abstr. #9508

Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Juergen Wolf et al, ASCO20 virtual, Abstr. #9509

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. Egbert F. Smit et al., ASCO20 virtual, Abstr. # 9504

Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Solange Peters et al., ASCO20 virtual, Abstr. #9518

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L. D. Ross Camidge et al., ASCO20 virtual, Abstr. # 9517

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study. Luis G. Paz-Ares et al., ASCO20 virtual, Abstr. #9002

KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). Charles M. Rudin et al., ASCO20 virtual, Abstr. #9001

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. Ticiana Leal et al., ASCO20 virtual, Abstr. #9000

Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC). Bjorn Henning Gronberg et al., ASCO20 virtual, Abstr. #9007

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Delvys Rodriguez-Abreu et al., ASCO20 virtual, Abstr. #9503

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. Martin Reck et al., ASCO20 virtual, Abstr. #9501

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). Delvys Rodriguez-Abreu et al., ASCO20 virtual, Abstr. #

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. Suresh S. Ramalingam et al., ASCO20 virtual, Abstr. #9500

 PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. Patrick M. Forde et al., ASCO20 virtual, Abstr. #9003

Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study. Maria Pagano et al., ASCO20 virtual, Abstr. #9004